ABBV
New lab partner, same old race
AbbVie says it’s entering a multi-year collaboration with Iambic, a clinical-stage life sciences and tech company, to accelerate the discovery and development of small molecule therapies. Translation: AbbVie is bringing in an AI-flavored co-pilot to help sift through the chemical haystack faster.
Why investors should squint at this
Drug discovery is expensive, slow, and full of dead ends — basically the world’s most glamorous game of whack-a-mole. If this collaboration helps AbbVie identify promising candidates sooner, that could improve pipeline productivity and potentially give the company a few more shots on goal across immunology and other areas.
The AI angle is doing a lot of heavy lifting
Iambic isn’t just a random vendor; it’s pitching AI-enabled discovery as a way to make the early R&D grind less of a moonshot. For AbbVie, partnerships like this are less about instant revenue and more about building a future pipeline that doesn’t look like it was assembled with duct tape and prayer.
Big picture: this is a classic pharma move — spend now, hope the science ages like wine instead of milk later.